Bionomics Appoints Dr Spyros Papapetropoulos as President and CEO
- Biopharmaceutical company, Bionomics (BNO), appoints neuroscientist Dr Spyros Papapetropoulos (MD) as its new President and Chief Executive Officer
- Dr Papapetropoulos will step into the role on January 5, 2023, which will see him receive US$525,000 (AU$782,500) per annum
- Executive Chair Errol B. De Souza will be transitioning from Executive to Non-Executive Chair, starting the new position on January 1
- Dr Papapetropoulos is a recognised neuroscientist and neurologist and has 25 years working in companies focused on central nervous system
- He has held a number of senior and executive positions at large biopharmaceutical companies, most recently as Chief Medical Officer of Nasdaq-listed Vigil Neuroscience
- BNO shares are up 9.62 per cent, trading at 5.7 cents at 1:30 pm AEDT
